drugset / Trial / NCT00410423
Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias
Phase 1/2
Completed
55 enrolled
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Millennium Pharmaceuticals, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Based on what is known about it's mechanism of action, bortezomib is presumed to make other chemotherapy drugs work better. This study examines the use of bortezomib in combination with an already effective chemotherapy regimen that is used to treat leukemias that have relapsed or been refractory to treatment.
Timeline
- Start
- 2006-01
- Primary completion
- 2013-05
- Completion
- 2014-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 0.7 mg/m2 | Intravenous |
| Subject | Bortezomib | Small molecule | 1 mg/m2 | Intravenous |
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Background | Cytarabine | Small molecule | — | — |
| Background | Etoposide | Small molecule | — | — |
| Background | Mitoxantrone | Small molecule | — | — |
Indications
No indication recorded.